News
![FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)
Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved NYVEPRIA™ (pegfilgrastim-apgf), a biosimilar to Neulasta® (pegfilgrastim).1 NYVEPRIA
![Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12
![Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test
Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use
![Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![New Capability in Vault PromoMats to Speed Packaging Promotional Materials for FDA Submission](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
New Capability in Vault PromoMats to Speed Packaging Promotional Materials for FDA Submission
Veeva Systems (NYSE: VEEV) today announced at Veeva Summit Online a new capability in Veeva Vault PromoMats to speed the digital submission of promotional materials for accelerated approval
![Veeva Announces New Solution to Accelerate Insights for Key Account Management](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Veeva Announces New Solution to Accelerate Insights for Key Account Management
Today at Veeva Summit Online, Veeva Systems (NYSE: VEEV) announced Veeva Link for KAM, a new solution that gives commercial and medical teams accurate customer data and real-time insights for key
![Technology Veteran Brent Bowman to Become Veeva Chief Financial Officer](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Technology Veteran Brent Bowman to Become Veeva Chief Financial Officer
Veeva Systems (NYSE: VEEV) today announced that Brent Bowman will become the company’s next chief financial officer. Bowman will assume the role of CFO after a transition period of approximately 90
![Dexcom Announces Upcoming Conference Presentation](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:
-
Steve Pacelli, Executive Vice President, Strategy and
![Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology
Pfizer Inc. (NYSE: PFE) announced today that JAMA Dermatology has published complete results from the second Phase 3 monotherapy pivotal study (JADE MONO-2) of abrocitinib, an investigational oral
![Humana Announces Support for Louisville to Help Rebuild and Unite City](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Humana Announces Support for Louisville to Help Rebuild and Unite City
Today, Humana (NYSE: HUM) announced actions to support its hometown of Louisville in its efforts to address racial inequity and unite toward a stronger community.
“We are at a pivotal moment in
![Life Sciences Accelerates Use of Remote Meetings to Connect with Healthcare Professionals](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Life Sciences Accelerates Use of Remote Meetings to Connect with Healthcare Professionals
Leveraging digital channels to connect with healthcare professionals (HCPs) is a top priority across the life sciences industry. To accelerate the move toward digital engagement, increasing numbers
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 41st Annual
![Pfizer Establishes New Program to Support Continued Biotechnology Innovation](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Pfizer Establishes New Program to Support Continued Biotechnology Innovation
Pfizer Inc. (NYSE: PFE) today announced the establishment of the Pfizer Breakthrough Growth Initiative, through which Pfizer will invest up to $500 million in biotechnology companies to help
![Agilent Technologies Announces Pricing of $500 Million of Senior Notes](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Agilent Technologies Announces Pricing of $500 Million of Senior Notes
Agilent Technologies, Inc. (NYSE: A) today announced the pricing of an underwritten, registered public offering of a series of its senior notes in an aggregate principal amount of $500 million. The
![Agilent Technologies Announces Proposed Offering of Senior Notes](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Agilent Technologies Announces Proposed Offering of Senior Notes
Agilent Technologies Inc. (NYSE:A) today announced it is offering, subject to market and other conditions, a series of senior notes under an automatic shelf registration statement on file with the
![Agilent Announces New Mass Spectrometry Products at ASMS 2020 Reboot](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Agilent Announces New Mass Spectrometry Products at ASMS 2020 Reboot
Agilent Technologies Inc. (NYSE: A) today announced two new mass spectrometry (MS) products: the Agilent 6470B Triple Quadrupole LC/MS (6470 LC/TQ) system, and the Agilent RapidFire 400 system
![Humana Awarded New Contract to Continue Serving Medicaid Managed Care Residents in Home State of Kentucky](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Humana Awarded New Contract to Continue Serving Medicaid Managed Care Residents in Home State of Kentucky
Humana Inc. (NYSE: HUM) has been selected by the Kentucky Cabinet for Health and Family Services (CHFS) to continue serving children and adults across the health company’s home state of Kentucky
![Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer
As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a preplanned efficacy and futility
![Veeva Announces Fiscal 2021 First Quarter Results](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Veeva Announces Fiscal 2021 First Quarter Results
Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fiscal first quarter ended April 30, 2020.
![Agilent to Present at Jefferies Virtual Healthcare Conference](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Agilent to Present at Jefferies Virtual Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced the following webcast for the investment community.
Jefferies Virtual Healthcare Conference
Wednesday, June 3, 2020 at 1:00 p.m. (ET)
![Quidel to Present Virtually at William Blair 40th Annual Growth Stock Conference](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Quidel to Present Virtually at William Blair 40th Annual Growth Stock Conference
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the
![Louisville Nonprofits Receive $2.2 Million through Humana Foundation’s Community Partners Program](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Louisville Nonprofits Receive $2.2 Million through Humana Foundation’s Community Partners Program
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 38 years, is awarding $2.2 million to nonprofit organizations in Louisville as part of its ongoing Community
![Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
Pfizer Inc. (NYSE: PFE) today announced that it and Wyeth recommend rejection of the unsolicited tender offer made by Huguenot Bond Liquidity, LLC (“Offeror”) on May 11, 2020 (as amended and
![Agilent Reports Second-Quarter Fiscal Year 2020 Financial Results](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Agilent Reports Second-Quarter Fiscal Year 2020 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.24 billion for the second quarter ended April 30, 2020, equal to revenue reported for the second quarter of 2019 and down 1.7% on a
![Top Pharmaceutical Company Visionaries to Keynote Veeva Summit Online](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Top Pharmaceutical Company Visionaries to Keynote Veeva Summit Online
Veeva Systems (NYSE: VEEV) today announced that Barry Greene, president at Alnylam Pharmaceuticals, and Andy Schmeltz, global president and general manager of oncology at Pfizer Inc., will be